Brickell Biotech Receivables

Brickell Biotech posts a receivables of $360K as of June 2022. In the prior-year period, the figure was $0. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Brickell Biotech's receivables was $0. The latest reading is $360K (period ending June 2022). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Brickell Biotech's financial statement story. At $360K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BBI's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Brickell Biotech's other metric pages and overview cover the third.

Judging Brickell Biotech against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $360K here, then scan peer and history charts to see if the gap is persistent.